Psychiatr. pro Praxi, 2006; 5: 254-256

Věrná společnice

MUDr. Iveta Zedková, MUDr. Zdeněk Faldyna
Psychiatrická klinika FN a LF UP, Olomouc

Kazuistika pojednává o problematice dystymie, jejíž průběh i léčba jsou často komplikované i přes rozsáhlé znalosti biologických i psychodynamických faktorů, které přispívají k jejímu vzniku a udržování. Popisuje moderní přístup k léčbě, ke kterému v současnosti patří jak psychofarmaka, tak i psychoterapie. Znalosti o neurotransmisi, ale i klinická zkušenost prokazují dobrý efekt látek působících na dopaminergní a serotonergní systém. Psychoterapie se zaměřuje na vztahovou problematiku a psychosociální fungování klientů trpících tímto v mnoha případech chronickým onemocněním. Sdělení zachycuje dynamiku vývoje pacientových potíží, ale také svízelnost a frustraci, které terapii provázejí.

Published: December 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zedková I, Faldyna Z. Věrná společnice. Psychiatr. praxi. 2006;7(5):254-256.
Download citation

References

  1. Berger M. et al. Psychische Erkrankungen. Klinik und Therapie; Urban & Fischer Bei Elsevier; 2. Aufl., Sept. 2003.
  2. Browne G. Steiner M. et al. Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6month comparison with longitudinal 2-year follow-up of effectiveness and costs. J Affect Disord, 2002 Apr; 68 (2-3): 317-30. Go to original source... Go to PubMed...
  3. De Lima MS, Hotopf M. Benefits and risks of pharmacotherapy for dysthymia: a systematic appraisal of the evidence. Drug Saf. 2003; 26(1): 55-64. Go to original source... Go to PubMed...
  4. Klein DN, Schwartz JE Five-year course and outcome of dysthymic disorder: A prospective, naturalistic lollow-up study. Am J.Psychiatry, 2000 Jun; 157 (6): 931-9. Go to original source... Go to PubMed...
  5. Markowitz JC Psychotherapy for dysthymic disorder. Psychiart Clin North Am. 1996 Mar; 19 (1): 133-49. Go to original source... Go to PubMed...
  6. Markowitz J, Kocsis J. et al. A comparative trial of psychotherapy and pharmacotherapy for "pure" dysthymic patients. J Affect Disord. 2005 Dec;89 (1-3): 167-75. Go to original source... Go to PubMed...
  7. Markowitz JC, Moran ME et al. Prevalence and comorbidity of dysthymic disorder among psychiatric outpatients. J Affect Disord., 1992 feb; 24 (2): 63-71. Go to original source... Go to PubMed...
  8. McCullough JP Cognitive-behavioral analysis system of psychotherapy: An interactional treatement approach for dysthymic disorder. Pychiatry, 1984, 47: 234-50.
  9. McCullough, JP Psychotherapy for dysthymia: Naturalistic study of ten cases. J Nerv Mental Disease, 1991, 179: 734-40. Go to original source...
  10. McCullough JP Cognitive Behavioral System of Psychotherapy: Treatment for Chronic Depression. In JC. Norcross & MR. Goldfried (Eds.), Handbook of Psychotherapy Integration (2nd ed.). London: Oxford Univ Press, Chapter 13, pp. 281-98.
  11. McFarland BR, Klein, DN Mental health service use by patients withdysthymic disorder: treatment useand dropout in a 7-year naturalistic follow-up study. Cmpr Psychiatry 2005 Jul-Aug; 46 (4): 246-53. Go to original source... Go to PubMed...
  12. Montgomery SA Dopaminergic deficit and the role of amisulpiride in the treatment of mood disorders. Int Clin Psychopharmacol, 2002 Dec; 17 Suppl 4: S9-15. Go to PubMed...
  13. Pani L. Gessa GL et al. The role of dopamine in the biological basis of dysthymia. Italianj Psychiatry Behav Sci 1998; 8: 5-9.
  14. Praško J, Herman E. et al. Dysthymie - Příručka pro klinickou praxi, Maxdorf, 2003.
  15. Riso L, Klein D. et al. Understanding the comorbidity between early-onset dysthymia and cluster B personality disorders: a family study.Am J Psychiatry,1997 Jul; 154 (7): 1039-40.
  16. Švestka J. Amisulpirid - atypický preparát ve skupině antipsychotik 2. generace. Psychiatrie 2000; 4: 191-200.
  17. Shem S. Dům páně, Argo 1999.




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.